- The Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus intravenous infusion, resulted in a relatively flat plateau of blood concentration of the drug with very slow decline over a 24 hour period in a cynomolgus monkey model.
- The maximum concentration as well as the plateau concentration increased in a dose-dependent manner, as expected.
NanoViricides Reports On The Highly Desirable Blood Concentration Profile Of Its Lead Clinical Stage Broad-spectrum Antiviral Agent NV-387 Upon Intravenous Administration In A Non-human Primate Animal Model
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated